Table 2.
Primary ESS | Revision ESS | P value | |
---|---|---|---|
N = 19 | N = 19 | ||
Baseline clinical characteristics (N = 38) | |||
Clinical characteristics | |||
Men/women, N/N (%/%) | 13/6 (68/32) | 12/7 (63/37) | 1.00 |
Age (y), median (IQR) | 44 (31–54) | 47 (37–53) | 0.863 |
Comorbidity | |||
Allergic sensitizaion, N (%) | 10 (53) | 10 (53) | 1.00 |
Asthma, N (%) | 5 (26) | 10 (53) | 0.184 |
AERD, N (%) | 3 (16) | 7 (37) | 0.269 |
Total NP score, median (IQR) | 4 (3–5) | 4 (4–6) | 0.644 |
Total symptom score, median (IQR) | 8 (7–12) | 9 (8–12) | 0.443 |
Tissue biomarkers, median (IQR) | |||
IL-5 (pg/ml) | 86.02 (43.00–237.87) | 228.14 (133.24–484.44) | < 0.05 |
Detectable IL-5, N (%) | 10 (53) | 16 (84) | 0.079 |
IL-5Rα (pg/ml) | 2704.74 (1116.04–13,162.88) | 15,383.50 (4036.26–28,350.59) | < 0.05 |
TGF-β1 (pg/ml) | 8934.18 (7356.03–15,825.42) | 12,769.26 (7562.52–27,256.90) | 0.477 |
MPO (ng/ml) | 5251.91 (2634.00–11,020.06) | 9255.17 (4602.93–19,868.30) | 0.061 |
IL-18 (pg/ml) | 14,982.30 (7761.63–25,611.80) | 15,051.30 (4698.93–19,633.68) | 0.354 |
ECP (mg/l) | 5.71 (0.86–12.93) | 13.48 (4.75–28.46) | < 0.05 |
Total IgE (kU/l) | 322.95 (146.30–1348.16) | 432.30 (251.83–1156.39) | 0.639 |
Detectable IgE to SAE, N (%) | 8 (42) | 8 (42) | 1.00 |
Nasal secretion biomarkers, median (IQR) | |||
IL-5 (pg/ml) | 30.00 (30.00–109.22) | 94.81 (30.00–169.86) | 0.285 |
IL-5Rα (pg/ml) | 667.55 (439.40–791.74) | 2897.67 (562.93–10,030.07) | 0.076 |
ECP (mg/l) | 0.36 (0.12–0.79) | 0.54 (0.32–3.57) | 0.100 |
IgE (kU/l) | 174.15 (40.49–312.94) | 324.35 (100.14–662.78) | 0.394 |
Serum biomarkers, median (IQR) | |||
IL-5 (pg/ml) | BDL | BDL | ND |
IL-5Ra (pg/ml) | 334.60 (235.60–710.05) | 414.90 (364.30–866.60) | 0.471 |
ECP (µg/l) | 26.10 (21.60–45.15) | 23.90 (19.75–189.50) | 0.601 |
IgE (kU/l) | 217.00 (51.15–715.00) | 50.20 (29.35–189.50) | 0.110 |
Italic values indicate significance of P value (P < 0.05)
N number, IQR interquartile range, BDL below detection level, ND not done